RhinoPHAGE-2A

**RhinoPHAGE-2A** is an investigational bacteriophage cocktail being developed by the Hirszfeld Institute of Immunology and Experimental Therapy for chronic rhinosinusitis associated with *Staphylococcus aureus* infection. It is intended to use bacteriophages that selectively infect bacterial cells to reduce the *S. aureus* burden in the sinonasal tract. The exact component phages, phage genome characteristics, dose, formulation, and administration schedule have not been publicly identified. RhinoPHAGE-2A is the investigational product in EU CTIS trial 2024-516220-34-00, described as a randomized, multicentre, seamless adaptive Phase I/II safety-and-efficacy study. ([ctis.eu](https://www.ctis.eu/trial/2024-516220-34-00))